201 Elliott Avenue West
About Omeros Corporation
At Omeros, we are proud of our innovative and cutting-edge science. Our world-class team has achieved scientific advances that no other group has been able to accomplish, delivering wholly new classes of therapeutics to benefit patients. We let science lead the way.
From our foundation of groundbreaking science, we continue to build and advance a deep and diverse pipeline of small-molecule and protein therapeutics. We are not interested in developing “me-too” products; instead, we are focused on tackling challenging diseases and disorders with significant unmet medical needs. The result is an exciting pipeline of first-in-class drugs with new mechanisms of action that target previously untapped receptors and enzymes.
The Omeros team is exceptionally talented, passionate, collaborative and diverse. We hire smart, creative and hard-working people who want to play a meaningful part in building a preeminent biopharmaceutical company. We come from all corners of the globe, bringing unique abilities and experiences together to provide hope to patients and their families.
437 articles with Omeros Corporation
Omeros Corporation Receives $3.1 Million Milestone Payment from The Stanley Medical Research Institute for Schizophrenia Program
Omeros Corporation Awarded Grant from The Michael J. Fox Foundation to Evaluate Novel Parkinson's Disease Target
Omeros Corporation Announces Results from a Phase 1 Study of OMS201 for Use During Urological Surgery
Omeros Corporation and The Parkinson's Institute Clinical Center Enter into a Collaboration Agreement to Evaluate Novel Target for the Treatment of Movement Disorders
Omeros Corporation Announces Publication of Clinical Results for OMS103HP in Arthroscopy: The Journal of Arthroscopic and Related Surgery
Omeros Corporation Acquires Nura, Inc.; Acquisition Adds World-Renowned Scientists And Expands Pipeline